Status:
COMPLETED
Assessing Adherence to Digital Health Technologies Among Hispanic/Latino Adults With or At Risk of Type 2 Diabetes:
Lead Sponsor:
Sansum Diabetes Research Institute
Collaborating Sponsors:
William Marsh Rice University
Carnegie Mellon University
Conditions:
Diabetes Mellitus, Type 2
Depression
Eligibility:
All Genders
18+ years
Brief Summary
In an effort to personalize medical care, novel approaches have been used to categorize sub-populations of patients with type 2 diabetes (T2D). These are based on biological and genetic variables, all...
Detailed Description
As treatment choices for type 2 diabetes (T2D) evolve from a one-size-fits-all approach into a patient-centered precision medicine model, there is a need for a deeper understanding of the clinically m...
Eligibility Criteria
Inclusion
- Adults ≥ 18 years of age at Visit 1.
- Self-reported Hispanic/Latino heritage.
- Self-reported diagnosis of type 2 diabetes OR self-reported as at risk for developing type 2 diabetes OR healthy individuals who are not at-risk or have diabetes (healthy controls).
- Based on staff's judgment, the subject must have a good understanding, ability, and willingness to adhere to the protocol and to participate in the video-recording part of the study.
- Exclusive and continuous use, for the 2 week participation period, of a study-compatible smartphone.
Exclusion
- Currently taking insulin as treatment for diabetes.
- Pregnant.
- Any active clinically significant disease or disorder, which in the investigator's opinion could interfere with the participation in the trial.
- Mental incapacity, psychiatric disorder, unwillingness or language barriers precluding comprehension of study activities and informed consent.
- Current participation in other trials involving medications or devices.
- Meets criteria for substance use disorders as defined by DSM-5 (e.g., abuse of alcohol, narcotics, or illicit drugs).
- Self-reported diagnosis of bipolar disorder, schizoaffective disorder, schizophrenia or antisocial personality disorder.
- At high risk for suicide based on staff judgement.
- Neuromuscular disease.
Key Trial Info
Start Date :
April 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2021
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04820348
Start Date
April 9 2021
End Date
August 31 2021
Last Update
October 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sansum Diabetes Research Institute
Santa Barbara, California, United States, 93105